Novavax to Host Conference Call to Discuss Third Quarter 2017 Financial Results on November 7, 2017
GAITHERSBURG, Md., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter financial and operating results following the close of U.S. financial markets on Tuesday, November 7, 2017.
Conference call details are as follows:
| Date: | Tuesday, November 7, 2017 |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Passcode: | 2479419 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call and webcast replay:
| Dates: | Starts at 7:30 p.m. ET, Nov. 7, 2017 until 7:30 p.m. ET, Nov. 14, 2017 |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: | 2479419 |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until February 7, 2018 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact:
Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor & Media Relations
ir@novavax.com
240-268-2000
Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506
Media
Russo Partners, LLC
David Schull
Maggie Beller
david.schull@russopartnersllc.com
maggie.beller@russopartnersllc.com
212-845-4271
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
